Ipsen SA

→ Ex- Citi analyst Andrew Baum has left his role as chief strategy and innovation officer at Pfizer , but he will be a senior strategic advisor to CEO Albert Bourla . BMO Capital Markets broke the news in a Monday note. Baum came to Pfizer in June 2024 as the pharma giant grappled with its post-Covid future and watched its shares lose more than half their value from the previous year. There has been an incremental year-to-date recovery, but we’re far from the days of the Covid boom. In a statement sent to Endpoints News , Pfizer said it has initiated a reorg within the strategy and business innovation team “to position Pfizer to move faster, make clearer decisions, and advance innovation across the enterprise.” Pfizer did win a crucial battle in the obesity space last fall by thwarting Novo Nordisk and buying Metsera . → In a rapid change of heart that came at the direction of the board, Michael Cola was asked to step down immediately as CEO of Helus Pharma , the company announced this week. Cola joined in February and replaced Doug Drysdale , who had led the company (formerly known as Cybin ) for more than five years. He’ll be replaced on an interim basis by executive chairman Eric So , who also temporarily led the company after Drysdale stepped down in September 2025. Cola was meant to add large pharma experience at a critical moment, as Helus advances its psilocybin analog through a Phase 3 trial with a key readout that’s expected before the end of the year. Despite not having the same name recognition as some of the other psychedelic companies, Helus is one of the closest to potential FDA filing. Cola was previously president of Shire ’s specialty pharma business, with earlier stints at AstraZeneca . He was also the CEO of Avalo Therapeutics . Before the week ended, Helus appointed Moderna co-founder Bob Langer and former Karuna Pharmaceuticals CMO Stephen Brannan to its scientific advisory board. → BioMarin chairman Randy Meier is retiring, and ex- Genentech CEO Ian Clark is slated to take over once stockholders have their say at the company’s annual meeting in June. CEO Alexander Hardy — who also once led Genentech — said in a statement that Meier “has helped guide BioMarin through a period of meaningful growth and transformation” throughout his 20-year tenure on the board. Meier succeeded Jean-Jacques Bienaimé as chairman in 2023, while Clark joined the board last summer. The move comes after BioMarin pulled the plug on its $2.9 million gene therapy Roctavian . → There will be a changing of the guard at Chiesi as group CEO Giuseppe Accogli departs on May 15. Group CFO Jean-Marc Bellemin will fill in as interim chief until a successor is named at the Italian pharma. Accogli had a 16-year career at Baxter before he succeeded Ugo Di Francesco in 2023. Chiesi is taking a dip into CRISPR through a deal with Arbor Biotechnologies that could be worth up to $2 billion. The partnership focuses on licensing and developing Arbor’s gene editing therapy for primary hyperoxaluria type 1 called ABO-101 . Chinese biotech YolTech Therapeutics is also testing a CRISPR therapy for this rare genetic condition. → Former Aragon and Seragon leader Rich Heyman has decided to retire as chairman of p53 drug developer PMV Pharmaceuticals , and he’ll replaced by Laurie Stelzer . For nine months in 2025, Stelzer held the CFO post at obesity biotech Kailera Therapeutics , which just put together a record IPO last week. She has a history of CFO stints at biotechs that become M&A bait: Arena Pharmaceuticals ( bought by Pfizer); Mirati Therapeutics ( bought by Bristol Myers Squibb ); and Orna Therapeutics ( bought by Eli Lilly ). Stelzer is a board member at Sionna Therapeutics , Spyre Therapeutics and MBX Biosciences . → The allure of T cell engagers, one of the hottest modalities in biotech startup funding and pharma dealmaking, has caught Luis Borges . After four CSO posts since 2017, Borges is now tackling the duties of CEO at a Philadelphia biotech that he’s founded. Artemia Therapeutics appears to be only a few months old, according to Borges’ LinkedIn, and is currently seeking seed funding. “Artemia is built on a simple but powerful premise: to translate the clinical validation seen with cellular therapies into a more scalable, practical, and broadly accessible biologics modality,” he wrote in a LinkedIn post . Borges recently departed the CSO post at US and Japan cell therapy outfit Shinobi Therapeutics . Metagenomi , Century Therapeutics and Cell Medica have also relied on Borges for CSO responsibilities over the past decade. → Santhera CEO Dario Eklund is headed for the exit, and the Swiss biotech has already lined up Orlando Oliveira as his successor. Oliveira is scheduled to begin July 15 and has been chief commercial officer for Lonnie Moulder ’s crew at Zenas BioPharma for nearly two years. He was also head of international for Mirati Therapeutics from 2022-24. “After almost seven years in this role, I believe the time is right for a planned leadership transition,” Eklund said in a statement . “I have long believed that leadership renewal, at the right time, is healthy for companies — bringing fresh perspectives, renewed energy and support for the next phase of growth.” → Alicia Secor has flown into the bat cave. She’s taken on the CEO role at Paratus Sciences , which Polaris Partners and ARCH believe can turn bat biology into a launchpad for new medicines. When Theresa Heah stepped into the CEO post at Paratus two years ago, she caught our attention by saying she wished she were a bat because of the power of bat biology. The ability to manage inflammation, have longer health spans and other qualities were quite appealing. Heah has since gone on to lead ophthalmology group Eyexora , and her successor arrives after a brief break from the chief executive seat. Secor led RNAi startup Atalanta Therapeutics toward the clinic. For five years, she navigated the biotech-building process with one investor. Then, at the beginning of 2025, she secured the help of multiple investors in a $97 million Series B . And she’s bringing the CFO who helped engineer that financing with her. Jeffrey Young will take on the same duties at Paratus as the Boston and Singapore biotech gears up for the clinic with a pan-inflammasome inhibitor called PS-1001 . Ganesh Mugundu is also joining Paratus as head of clinical development. → Vir Biotechnology medical chief Mark Eisner has called it quits, according to an SEC filing . Eisner succeeded Phil Pang on June 3, 2024, and only lasted nine months in the same position at Sonoma Biotherapeutics . He spoke to Endpoints in November about the “very, very strong antiviral efficacy” that was seen in the mid-stage data for Vir’s hepatitis D combo regimen of tobevibart and elebsiran . → Ruxandra Draghia Akli left her role as Novavax ’s head of R&D earlier this month after about a year and a half, pursuing other opportunities. In a LinkedIn post , she thanked the company’s research and regulatory teams, writing that “every experiment run, every setback pushed through, and every breakthrough achieved reflects the very best of what science, and humanity, could and should do.” She has been replaced by Robert Walker , who was previously Novavax’s CMO. Walker had a brief stint at Meissa Vaccines before joining Novavax in 2022. He spent more than seven years at BARDA, a government agency tasked with financing and advancing early-stage biodefense projects, particularly preparing against pathogens and pandemics. → A spokesperson for Madrigal Pharmaceuticals tells Peer Review that the Rezdiffra maker has selected Ricardo Rocha as global head of medical affairs. Rocha had led the medical affairs team at Intellia Therapeutics since 2022 and served in numerous roles over a 19-year period at Novartis , including head of the cardiorenal & metabolism medical unit and regional medical head for the Latin America and Canada region. Looking to establish itself as the dominant force in the MASH field, Madrigal paid $60 million upfront in February for access to six siRNA candidates from Suzhou Ribo Life Science . → Sagimet Biosciences has a new medical chief. Eduardo Bruno Martins retired on Monday as Andreas Grauer takes on medical leadership at the metabolic and fibrosis company. Grauer previously held the same post at Omeros , Federation Bio and Corcept Therapeutics . Grauer joins Sagimet as the California biotech puts together the final touches on a Phase 2 study in MASH for the second half of this year. Its partner Ascletis has an acne treatment under regulatory review in China. → Edward Conner is leaping from company to company at a feverish pace, landing at Paragon ’s autoimmune spinoff Jade Biosciences for his fourth CMO job in five years. Conner left Astellas Gene Therapies in 2021 to become CMO of Locanabio , and a year later he was off to Third Harmonic Bio in the same role. After Third Harmonic shut down last year, Conner was named CMO of Ardelyx in August. Atara Biotherapeutics vet Rajani Dinavahi just replaced him at Ardelyx this month. A crew from Chinook Therapeutics started Jade after selling itself to Novartis and took the place of Aerovate Therapeutics on the Nasdaq. → NovaBridge Biosciences , which you may remember from its days as I-Mab , has tapped Mark Hagler as president and chief commercial officer. Hagler was elevated to commercial chief during a 10-year career at Sun Pharma , and he’s also been head of oncology marketing for Ipsen . NovaBridge has two bispecific antibodies in mid-stage development: givastomig (Claudin18.2×4-1BB) and VIS-101 (VEGF-AxANG-2). → Radius Health CFO and head of operations Bethany Sensenig has stepped down after Radius merged with Paratek Pharmaceuticals . On April 15, the Biogen vet also picked up a seat on the board of directors at Vancouver-based neuro biotech Alpha Cognition . You can also find her in the boardrooms at Ekterly maker KalVista Pharmaceuticals and Supernus Pharmaceuticals . → Christy Shafer will prepare Neurogene for the potential launch of its Rett syndrome gene therapy NGN-401 as chief commercial officer. Neurogene also said that president and CFO Christine Mikail has joined the board of directors. Shafer caught the attention of Peer Review in 2020, when she was named chief commercial officer at Marinus Pharmaceuticals . In March 2025, she became general manager, North America for Avidity Biosciences , the RNA specialist that Novartis bought for $12 billion. In November 2024, early results for NGN-401 were marred by the death of a Rett syndrome patient. → We have two new execs to discuss at Copenhagen-based MinervaX , which is developing a vaccine for group B Streptococcus : Chief development officer Jamila Louahed was global head of therapeutic vaccines R&D during a long career at GSK , and finance chief Hans Henrik Chrois Christensen spent six years with ImCheck Therapeutics as CFO and COO. Ipsen acquired ImCheck late last year for €350 million upfront. And while we’re thinking of ImCheck, its former CEO Pierre d’Epenoux is the newest board member at French neuropsychiatry biotech Elkedonia . → Dutch protein degradation shop Laigo Bio has welcomed Richard Sainson as CSO. Sainson worked at Paris-based Advesya in the same capacity from 2023-25, and he was VP of translational development for F-star Therapeutics . Hans Clevers , the former head of Roche ’s pharma research and early development (pRED) organization, leads a trio of additions to Laigo Bio’s scientific advisory board. → Felecia Ettenberg has replaced Elizabeth Grammer as chief legal officer at Ardelyx. Ettenberg held numerous roles over a 25-year career with Bristol Myers, including deputy general counsel, pipeline to patient global law. Grammer jumped to the Ardelyx team full time in 2012 and sits on the board at Sagimet Biosciences. → The next phase of Andrew Chan ’s career is starting to take shape, first as a venture partner at The Column Group and now as the new addition to the board of directors at Corvus Pharmaceuticals . Chan finished a 15-year run at Genentech as SVP, research biology, and spent more than two decades with the company overall. Corvus’ shares $CRVS soared in January after its Phase 1 readout for soquelitinib in severe atopic dermatitis. Endpoints is fielding the next Biopharma Sentiment Index (BPSI) — a concise, three-minute survey that distills thousands of industry views into a clear quarterly benchmark. This year is pivotal for biopharma, and we need your perspective on where things are going. Take the survey here.

Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDA TM in the U.S . in pediatric low-grade glioma. Transaction also includes a strong oncology pipeline of clinical stage assets in rare cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 billion. SURESNES, France , April 23, 2026 /CNW/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced the successful completion of the tender offer to acquire all of the issued and outstanding shares of common stock of Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, for $21.50 per share. The acquisition strengthens Servier's leadership in low-grade glioma and expands the Group's position in oncology with the addition of a marketed product and pipeline focused on rare cancers. "This acquisition represents a significant step forward for Servier as part of our 2030 ambition to strengthen our position in rare cancers, and more specifically in pediatric low-grade glioma," said Olivier Laureau, President of Servier . "Integrating Day One's scientific and clinical capabilities will enhance our Group's ability to support long-term innovation and translate science into meaningful medicines for children and families affected by rare cancers." Day One's portfolio includes OJEMDA TM (tovorafenib), an FDA-approved medicine in pediatric low-grade glioma, the most common form of childhood brain tumor. Day One already markets the product in the United States and has licensed the rights outside the U.S. to Ipsen. The transaction also strengthens Servier's oncology pipeline from early clinical to Phase 3. In addition to tovorafenib, which is being investigated in additional indications, Day One's pipeline includes Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC) and DAY301, a targeted therapy in rare cancers. "Welcoming Day One to Servier marks an important next chapter in how we are expanding our presence in oncology in the U.S. and strengthening our ability to deliver for patients," said David K. Lee, Executive Vice President, USA, and CEO, Servier Pharmaceuticals . "Day One is joining us with strong science, an approved medicine, and a team that knows how to turn innovation into real outcomes for patients. This is about combining focus with execution to deliver for patients with rare cancers." Contacts Servier Group Laura Visserias laura.visserias.part@servier.com Servier Pharmaceuticals (U.S.) Paulina Bucko paulina.bucko@servier.com PDF: Logo: View original content to download multimedia: SOURCE Servier

Total sales growth of 22.6% at CER 1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline ® , growing by 27.5% at CER Strong pipeline momentum with three Phase III readouts expected in H2 2026 Confirmation of full-year 2026 guidance 2 PARIS, FRANCE, 23 April 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2026. Q1 2026 % change €m Actual CER Oncology 707.5 8.0 % 13.0 % Rare Disease 147.1 109.1 % 125.4 % Neuroscience 220.3 13.8 % 18.5 % Total Sales 1,074.9 17.0% 22.6% “Ipsen has delivered a strong start to 2026,” said David Loew, Chief Executive Officer, Ipsen. “We advanced our strategic priorities across the business, combining strong top‑line performance with continued pipeline progress. I am very pleased with the growth of our rare liver disease franchise with the performance of Iqirvo and Bylvay. Additionally, with three Phase III readouts expected this year and three new late-stage programs starting, Ipsen is well-positioned to drive sustainable growth and deliver meaningful value for patients.” Full-year guidance 2026 Ipsen is confirming its financial guidance 3 for full-year 2026: Total sales growth greater than 13.0%, at constant currency, assuming accelerated sales growth of the portfolio excluding Somatuline and the growth of Somatuline sales due to generic lanreotide challenges. Based on the average level of exchange rates in March 2026, an adverse effect on total sales of around 1% of currencies is expected Core operating margin greater than 35.0% of total sales Upcoming 2026 milestones Ipsen anticipates several key milestones across its portfolio in 2026, including: Iqirvo ® (ELSPIRE trial) – Readout of pivotal Phase III in primary biliary cholangitis Bylvay ® (BOLD trial) – Readout of pivotal Phase III in biliary atresia Dysport ® (BEOND trials) – Readout of pivotal Phase III trials in chronic and episodic migraine Corabotase (IPN10200, LANTIC trial) – Readout of Phase II in lateral canthal lines and forehead lines Data from stage 1 of the Phase II LANTIC trial of corabotase (IPN10200) will be presented at the Music City SCALE (Symposium for Cosmetic Advances and Laser Education) 2026 symposium in May. Pipeline update On 30 January 2026, Ipsen expanded its pre‑clinical pipeline in rare neurodegenerative diseases through a global collaboration and exclusive option agreement with Origami Therapeutics. The partnership focuses on a research‑stage protein‑degrader program targeting genetic neurodegenerative diseases. Should Ipsen exercise its option following successful drug‑candidate nomination, the Company would assume full responsibility for global development and commercialization, reinforcing its strategy in rare neuroscience and first‑in‑class innovation. On 9 March 2026, Ipsen announced the voluntary withdrawal of Tazverik ® (tazemetostat) from all indications and all Ipsen markets, effective immediately, following emerging safety data from the ongoing Phase Ib/III SYMPHONY‑1 trial in follicular lymphoma. On 22 April 2026, following the positive European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) opinion, Ipsen was granted conditional marketing authorization by the European Commission (EC) for Ojemda ® (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement or BRAF V600 mutation, who have progressed after one or more prior systemic therapies. Approval is based on the pivotal Phase II FIREFLY-1 data demonstrating meaningful and durable tumor responses. Conference call A conference call and webcast for investors and analysts will begin today at 2pm CET. Participants can access the call and its details by registering here ; webcast details can be found here . Calendar Ipsen intends to publish its half-year results on 30 July 2026. Notes All financial figures are in € millions (€m). The performance shown in this announcement covers the three-month period to 31 March 2026 (Q1 2026, the quarter), compared to the three-month period to 31 March 2025 (Q1 2025) unless stated otherwise. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com . Ipsen Contacts Investors Henry Wheeler henry.wheeler@ipsen.com +33 7 66 47 11 49 Khalid Deojee khalid.deojee@ipsen.com +33 6 66 01 95 26 Media Sally Bain sally.bain@ipsen.com +1 857 320 0517 Anne Liontas anne.liontas.ext@ipsen.com +33 7 67 34 72 96 Disclaimers and/or forward-looking statements The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers . The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com . 1 At constant exchange rates (CER), which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period. 2 Total sales growth greater than 13.0%, at constant currency and core operating margin greater than 35.0% of total sales. 3 Excludes any impact from potential late-stage (Phase III clinical development or later) business development transactions. Attachment Ipsen PR_Q1 2026_23042026